Immunotherapy Updates:

Therapeutic benefit of baseline PSA: Lower baseline PSA is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial

by Leonard Gomella, MD

Leonard Gomella, MD of the Jefferson Kimmel Cancer Center Network discusses newly updated data from the Immunotherapy for Prostate Adenocarcenoma Treatment (IMPACT) trial

Castration-resistant prostate cancer: AUA Guideline 2013 commentary

by E. David Crawford, MD

E. David Crawford, MD, head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus in Aurora, Colorado, discusses the newly-released 2013 AUA Guideline for the treatment of patients with castration-resistant prostate cancer.

Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial

The findings in this exploratory analysis suggest that patients with less advanced disease may benefit the most from treatment with sipuleucel-T, providing a rationale for immunotherapy as an early step in the sequencing of treatment algorithms for mCRPC.

Understanding and implementing immunotherapy for prostate cancer

by Charles G. Drake, MD, PhD

Charles G. Drake, MD, PhD of Johns Hopkins Kimmel Cancer Center discusses the rationale of immunotherapy and our understanding of immunotherapy in the clinic.  He then reviews three products in research or in practice; ideas of combining androgen ablation and immunotherapy as we understand it today.

A review of emerging strategies for optimizing the clinical impact of immunotherapeutic agents in prostate cancer

The potential role of immunotherapy in the clinical management of malignancies has been debated for decades by researchers and medical oncologists. The discussion has been taken to a more practical level with the FDA approval of sipuleucel-T, the first personalized immunotherapy that activates the patient’s own immune cells to target and attack prostate cancer cells.

Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy in patients with biochemically-recurrent prostate cancer, by Emmanuel S. Antonarakis, MD, et al.

Interim analysis from a Phase II trial evaluating sequencing of ADT and the immunotherapy “vaccine” sipuleucel-T in 68 men with biochemically-recurrent prostate cancer who were randomized over nine months is presented.

Includes Session Highlights, Poster, and Podcast

Large urology group spotlight on Lancaster Urology Group: An evolutionary approach to an ADT clinic where bone health is a priority, Interview with Paul R. Sieber, MD

At Lancaster Urology Cancer Center (Lancaster, PA), Paul Sieber, MD, urologist, is one of 12 physicians, and he is actively engaged in several clinical trials. He has been a champion of bone-health education, and in this interview, he addresses Lancaster Urology’s multi-disciplinary approach.

Charles G. Drake, MD, PhD answers commonly asked questions: immunotherapy treatment in prostate cancer

Charles G. Drake, MD, PhD, answers questions pertaining to the research, mechanisms and implementation of immunotherapy for prostate cancer.